Literature DB >> 10512367

Evidence for a functional role of the cholecystokinin-B/gastrin receptor in the human fetal and adult pancreas.

C Saillan-Barreau1, M Dufresne, P Clerc, D Sanchez, H Corominola, C Moriscot, O Guy-Crotte, C Escrieut, N Vaysse, R Gomis, N Tarasova, D Fourmy.   

Abstract

Gastrin (G) and cholecystokinin (CCK) are gastrointestinal neuropeptides that are released into circulation during a meal. G is also transiently expressed during embryogenic and early ontogenic development of the pancreas and is believed to act on islet-cell development. Both peptides act on pancreatic endocrine function; however, the effects are dependent on the species and on cellular and molecular underlying mechanisms that remain poorly characterized. Since CCK-B/G subtype receptor is predominant over the CCK-A subtype in the human pancreas, we hypothesized that it could be expressed by islet cells. Here we present reverse transcription-polymerase chain reaction and immunohistochemistry data demonstrating that the CCK-B/G receptor is expressed in islet cells and that islet glucagon-producing cells are the major site of CCK-B/G receptor expression in adult and fetal pancreas. Moreover, G immunoreactivity was detected in the fetal human pancreas at embryogenic week 22. G- and CCK-stimulated glucagon are released from purified human islets. Concentration of CCK and G eliciting a half-maximal level of glucagon secretion were 13 +/- 6 and 8 +/- 5 pmol/l, respectively. Maximal glucagon secretion was achieved in the presence of 30 pmol/l peptides and was similar to that obtained in the presence of 10 mmol/l L-arginine (1.6 pmol x ml(-1) x 90 min(-1)). The nonpeptide antagonist of the CCK-B/G receptor, RPR-101048, fully inhibited CCK- and G-stimulated glucagon secretion at 100 nmol/l concentration. These data are consistent with the view that the CCK-B/G receptor is involved in glucose homeostasis in adult humans and mediates the autocrine effects of G on islet differentiation and growth in the fetal pancreas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10512367     DOI: 10.2337/diabetes.48.10.2015

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  14 in total

1.  Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival.

Authors:  Jeremy A Lavine; Philipp W Raess; Donald S Stapleton; Mary E Rabaglia; Joshua I Suhonen; Kathryn L Schueler; James E Koltes; John A Dawson; Brian S Yandell; Linda C Samuelson; Margery C Beinfeld; Dawn Belt Davis; Marc K Hellerstein; Mark P Keller; Alan D Attie
Journal:  Endocrinology       Date:  2010-06-09       Impact factor: 4.736

2.  Randomized prospective trial of the effect of induced hypergastrinemia on the prevention of pancreatic atrophy after pancreatoduodenectomy in humans.

Authors:  Jin-Young Jang; Sun-Whe Kim; Joon-Koo Han; Sang-Jae Park; Youn-Chan Park; Young Joon Ahn; Yong-Hyun Park
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

Review 3.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

4.  Localization of cholecystokinin receptor subtypes in the endocine pancreas.

Authors:  Jean Morisset; Sophie Julien; Jean Lainé
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

5.  Effect of proton pump inhibitors on glycemic control in patients with diabetes.

Authors:  Kohzo Takebayashi; Toshihiko Inukai
Journal:  World J Diabetes       Date:  2015-08-25

Review 6.  Proton pump inhibitors: impact on glucose metabolism.

Authors:  Diana Boj-Carceller
Journal:  Endocrine       Date:  2012-08-12       Impact factor: 3.633

7.  Is there adaptation of the exocrine pancreas in wild animal? The case of the Roe deer.

Authors:  Paul Guilloteau; Francesca Vitari; Valérie Metzinger-Le Meuth; Laurence Le Normand; Véronique Romé; Gérard Savary; Luc Delaby; Cinzia Domeneghini; Jean Morisset
Journal:  BMC Vet Res       Date:  2012-05-28       Impact factor: 2.741

Review 8.  Cholecystokinin-From Local Gut Hormone to Ubiquitous Messenger.

Authors:  Jens F Rehfeld
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-13       Impact factor: 5.555

9.  Islets from human donors with higher but not lower hemoglobin A1c levels respond to gastrin treatment in vitro.

Authors:  Ayelet Lenz; Gal Lenz; Hsun Teresa Ku; Kevin Ferreri; Fouad Kandeel
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

Review 10.  Premises for Cholecystokinin and Gastrin Peptides in Diabetes Therapy.

Authors:  Jens F Rehfeld
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.